CG Oncology upsizes at-the-market offering to $550M after selling $250M; shares last at $53.72

Filed January 13, 2026 · ~1 min read

Key Changes

• high

  CG Oncology increased its at-the-market offering capacity from $250M to $550M, having already sold $250M of stock under the prior limit.

  The Offering verify on EDGAR →
• medium

  Net proceeds are earmarked for general corporate purposes, primarily cretostimogene R&D, regulatory approval, and commercialization preparation.

  Use of Proceeds verify on EDGAR →
• high

  New investors face immediate dilution of $40.10 per share, as the assumed $53.72 offering price far exceeds the $12.65 as-adjusted net tangible book value per share.

  Dilution verify on EDGAR →